Bolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.89 and traded as low as $3.95. Bolt Biotherapeutics shares last traded at $4.21, with a volume of 21,880 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Rodman & Renshaw assumed coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $34.67.

Bolt Biotherapeutics Stock Up 4.0%

The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.98. The firm’s 50 day simple moving average is $4.48 and its 200-day simple moving average is $4.89. The stock has a market capitalization of $8.08 million, a price-to-earnings ratio of -0.26 and a beta of 1.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative return on equity of 100.89% and a negative net margin of 455.15%. Equities analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in BOLT. Squarepoint Ops LLC grew its position in shares of Bolt Biotherapeutics by 19.8% in the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after acquiring an additional 2,448 shares during the period. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $85,000. Susquehanna International Group LLP bought a new position in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $112,000. Finally, T3 Companies LLC bought a new stake in Bolt Biotherapeutics in the 4th quarter valued at $208,000. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.